Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation

Datos Bibliográficos

ID16780353
AutoresMarcelo Cristiano de Azevedo Ramos (0000-0002-6088-8908, University Medical Center Groningen), Maria Aparecida Azevedo Koike Folgueira (0000-0001-9269-8052, University Medical Center Groningen), Simone Maistro (0000-0002-0937-2391, University Medical Center Groningen), Alessandro Gonçalves Campolina (0000-0002-0233-0797, University Medical Center Groningen), Patrícia Coelho De Soárez (0000-0001-8383-0728, University Medical Center Groningen), Geertruida H de Bock (0000-0003-3104-4471, University Medical Center Groningen), H Maria Dutilh Novaes (0000-0001-9849-0324, University Medical Center Groningen), Maria Del Pilar Estevez Diz, Maria Del Pilar Estevez-Diz (0000-0003-3176-9747, University Medical Center Groningen)
Año2018
Volumen52
Páginas94
Fecha de publicación2018-11-22
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaRevista de Saúde Pública (JOURNAL)
Identificadores de la revistaISSN: 0034-8910 • E-ISSN: 0034-8910
EditorialUniversidade de Sao Paulo, Agencia USP de Gestao da Informacao Academica (AGUIA) (PUBLISHER)
DOI10.11606/s1518-8787.2018052000643
PMID30517521
OpenAlexW2915076975
IdiomaEN
Citas recibidas1
Referencias citadas2

OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in BRCA1/2 genes and of preventative strategies for the relatives of patients diagnosed with ovarian cancer associated with this mutation. METHODS: The study analyzed the cost effectiveness by developing an analysis of the Markov decision process from the perspective of the National Health System. The strategies compared reflect upon the adoption of genetic testing and preventative strategies for relatives or the usual care currently proposed. The incremental cost-effectiveness ratio was expressed in terms of cost per case avoided. The sensitivity analysis was performed in a univariate and deterministic manner. RESULTS: The study showed increments for effectiveness and for costs when performing genetic testing and adopting prophylactic measures for family members. The incremental cost-effectiveness ratio was estimated at R$908.58 per case of cancer avoided, a figure considered lower than the study’s cost-effectiveness threshold (R$7,543.50). CONCLUSIONS: The program analyzed should be considered a cost-effective strategy for the national situation. Studies in various other countries have reached similar conclusions. One possible ramification of this research might the need to perform a budgetary-impact analysis of making the program one of the country’s health policies

Actuarial science · Biology · Business · Cancer · Cancer prevention · Cost effectiveness · Cost-effectiveness analysis · Cost–benefit analysis · Economics · Genetic testing · Machine learning · Marginal cost · Microeconomics · Risk analysis (engineering) · Univariate · BRCA gene mutations in cancer · Computer Science · Genomics and Rare Diseases · Health Systems, Economic Evaluations, Quality of Life · Internal Medicine · Medicine